```
RESULT 3
AAB92553
ID   AAB92553 standard; protein; 464 AA.
XX
AC   AAB92553;
XX
DT   26-JUN-2001  (first entry)
XX
DE   Human protein sequence SEQ ID NO:10739.
XX
KW   Human; primer; detection; diagnosis; antisense therapy; gene therapy.
XX
OS   Homo sapiens.
XX
PN   EP1074617-A2.
XX
PD   07-FEB-2001.
XX
PF   28-JUL-2000; 2000EP-00116126.
XX
PR   29-JUL-1999;   99JP-00248036.
PR   27-AUG-1999;   99JP-00300253.
PR   11-JAN-2000; 2000JP-00118776.
PR   02-MAY-2000; 2000JP-00183767.
PR   09-JUN-2000; 2000JP-00241899.
XX
PA   (HELI-) HELIX RES INST.
XX
PI   Ota T,  Isogai T,  Nishikawa T,  Hayashi K,  Saito K,  Yamamoto J;
PI   Ishii S,  Sugiyama T,  Wakamatsu A,  Nagai K,  Otsuki T;
XX
DR   WPI; 2001-318749/34.
XX
PT   Primer sets for synthesizing polynucleotides, particularly the 5602 full-
PT   length cDNAs defined in the specification, and for the detection and/or
PT   diagnosis of the abnormality of the proteins encoded by the full-length
PT   cDNAs.
XX
PS   Claim 8; SEQ ID NO 10739; 2537pp + Sequence Listing; English.
XX
CC   The present invention describes primer sets for synthesising 5602 full-
CC   length cDNAs defined in the specification. Where a primer set comprises:
CC   (a) an oligo-dT primer and an oligonucleotide complementary to the
CC   complementary strand of a polynucleotide which comprises one of the 5602
CC   nucleotide sequences defined in the specification, where the
CC   oligonucleotide comprises at least 15 nucleotides; or (b) a combination
CC   of an oligonucleotide comprising a sequence complementary to the
CC   complementary strand of a polynucleotide which comprises a 5'-end
CC   sequence and an oligonucleotide comprising a sequence complementary to a
CC   polynucleotide which comprises a 3'-end sequence, where the
CC   oligonucleotide comprises at least 15 nucleotides and the combination of
CC   the 5'-end sequence/3'-end sequence is selected from those defined in the
CC   specification. The primer sets can be used in antisense therapy and in
CC   gene therapy. The primers are useful for synthesising polynucleotides,
CC   particularly full-length cDNAs. The primers are also useful for the
CC   detection and/or diagnosis of the abnormality of the proteins encoded by
CC   the full-length cDNAs. The primers allow obtaining of the full-length
CC   cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC   AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to AAB95893
CC   represent human amino acid sequences; and AAH13629 to AAH13632 represent
CC   oligonucleotides, all of which are used in the exemplification of the
```

```
CC   present invention
XX
SQ   Sequence 464 AA;

  Query Match             99.6%;  Score 2431;  DB 4;  Length 464;
  Best Local Similarity   99.6%;  Pred. No. 9.2e-239;
  Matches  462;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          1 MPKKAKPTGSGKEEGPAPCKQMKLEAAGGPSALNFDSPSSLFESLISPIKTETFFKEFWE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPKKAKPTGSGKEEGPAPCKQMKLEAAGGPSALNFDSPSSLFESLISPIKTETFFKEFWE 60

Qy         61 QKPLLIQRDDPALATYYGSLFKLTDLKSLCSRGMYYGRDVNVCRCVNGKKKVLNKDGKAH 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 QKPLLIQRDDPALATYYGSLFKLTDLKSLCSRGMYYGRDVNVCRCVNGKKKVLNKDGKAH 120

Qy        121 FLQLRKDFDQKRATIQFHQPQRFKDELWRIQEKLECYFGSLVGSNVYITPAGSQGLPPHY 180
              |||||||||||||||||||||||||||||||| ||||||||||||||||||||
Db        121 FLQLRKDFDQKRATIQFHQPQRFKDELWRIQEKLECYFSSLVGSNVYITPAGSQGLPPHY 180

Qy        181 DDVEVFILQLEGEKHWRLYHPTVPLAREYSVEAEERIGRPVHEFMLKPGDLLYFPRGTIH 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 DDVEVFILQLEGEKHWRLYHPTVPLAREYSVEAEERIGRPVHEFMLKPGDLLYFPRGTIH 240

Qy        241 QADTPAGLAHSTHVTISTYQNNSWGDFLLDTISGLVFDTAKEDVELRTGIPRQLLLVEST 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 QADTPAGLAHSTHVTISTYQNNSWGDFLLDTISGLVFDTAKEDVELRTGIPRQLLLVEST 300

Qy        301 TVATRRLSGFLRTLADRLEGTKELLSSDMKKDFIMHRLPPYSAGDGAELSTPGGKLPRLD 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TVATRRLSGFLRTLADRLEGTKELLSSDMKKDFIMHRLPPYSAGDGAELSTPGGKLPRLD 360

Qy        361 SVVRLQFKDHIVLTVLPDQDQSDEAQEKMVYIYHSLKNSRETHMMGNEEETEFHGLRFPL 420
              |||||||||||||||||||||| ||||||||||||||||||||||||||||||||||||
Db        361 SVVRLQFKDHIVLTVLPDQDQSDETQEKMVYIYHSLKNSRETHMMGNEEETEFHGLRFPL 420

Qy        421 SHLDALKQIWNSPAISVKDLKLTTDEEKESLVLSLWTECLIQVV 464
              |||||||||||||||||||||||||||||||||||||||||||||
Db        421 SHLDALKQIWNSPAISVKDLKLTTDEEKESLVLSLWTECLIQVV 464
```